Alphatec (NASDAQ:ATEC – Get Free Report) had its target price dropped by equities researchers at Piper Sandler from $19.00 to $17.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical technology company’s stock. Piper Sandler’s price objective would indicate a potential upside of 53.02% from the company’s previous close.
Several other research analysts have also recently issued reports on ATEC. Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 target price on shares of Alphatec in a research report on Wednesday, March 20th. Needham & Company LLC restated a “buy” rating and set a $23.00 target price on shares of Alphatec in a research report on Wednesday. Wells Fargo & Company initiated coverage on shares of Alphatec in a research note on Friday, February 9th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.89.
Get Our Latest Analysis on Alphatec
Alphatec Stock Down 18.2 %
Alphatec (NASDAQ:ATEC – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $138.48 million for the quarter, compared to analysts’ expectations of $134.07 million. During the same period in the previous year, the company earned ($0.40) EPS. The firm’s revenue for the quarter was up 26.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Alphatec will post -1.1 earnings per share for the current fiscal year.
Insider Transactions at Alphatec
In other Alphatec news, EVP David Sponsel sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $16.16, for a total transaction of $40,400.00. Following the completion of the transaction, the executive vice president now owns 637,418 shares in the company, valued at approximately $10,300,674.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP David Sponsel sold 2,500 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $16.16, for a total value of $40,400.00. Following the completion of the sale, the executive vice president now directly owns 637,418 shares in the company, valued at $10,300,674.88. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Scott Lish sold 11,963 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $15.34, for a total transaction of $183,512.42. Following the transaction, the chief operating officer now owns 538,240 shares in the company, valued at approximately $8,256,601.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 285,069 shares of company stock valued at $3,971,495. 29.12% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Alphatec
A number of large investors have recently bought and sold shares of ATEC. RiverPark Advisors LLC bought a new stake in shares of Alphatec in the 3rd quarter valued at about $53,000. Provence Wealth Management Group purchased a new stake in Alphatec during the third quarter worth $56,000. Van ECK Associates Corp bought a new stake in Alphatec during the 3rd quarter valued at $113,000. Tidemark LLC purchased a new position in shares of Alphatec in the 4th quarter valued at $137,000. Finally, Amalgamated Bank raised its holdings in Alphatec by 7.3% in the fourth quarter. Amalgamated Bank now owns 9,720 shares of the medical technology company’s stock worth $147,000 after purchasing an additional 660 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.
Alphatec Company Profile
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Featured Stories
- Five stocks we like better than Alphatec
- ETF Screener: Uses and Step-by-Step Guide
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- Consumer Staples Stocks, Explained
- Generac Powers Ahead on the Electrification Mega-Trend
- Insider Selling Explained: Can it Inform Your Investing Choices?
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.